Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema
Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 week